Observational studyIntensive care medicine2015
Incidence, characteristics and outcome of ICU-acquired candidemia in India.
Observational study in Intensive care medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 221 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
221 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Candida tropicalis-A systematic review to inform the World Health Organization of a fungal priority pathogens list.Medical mycology · 2024Pooled it
- Risk of invasive candidiasis with prolonged duration of ICU stay: a systematic review and meta-analysis.BMJ open · 2020Pooled it
- Candida auris: A systematic review and meta-analysis of current updates on an emerging multidrug-resistant pathogen.MicrobiologyOpen · 2018Pooled it
- Clinical safety and efficacy of novel antifungal, fosmanogepix, for the treatment of candidaemia: results from a Phase 2 trial.The Journal of antimicrobial chemotherapy · 2023Trial
- Pathogenicity and virulence ofVirulence · 2026Review
- Review
- Risk Factors for Mortality Among Patients with Bloodstream Infection Caused byAntibiotics (Basel, Switzerland) · 2026Article
- Surveillance for Candida auris - United States, 2022-2024.Morbidity and mortality weekly report. Surveillance summaries (Washington, D.C. : 2002) · 2026Article
- Micafungin exposure drives multidrug resistance inbioRxiv : the preprint server for biology · 2026Article
- Large-scale investigation for antimicrobial activity reveals newly-identified defensive species across the healthy skin microbiome.Nature communications · 2026Article
- Review
- Emergence and Genomic Profiling of Multidrug-Resistant Candida auris Isolated from Intensive Care Unit Patients in a Malaysian Teaching Hospital.Mycopathologia · 2026Article
- Genomic insights into a clade-specificmBio · 2026Article
- Candida auris: a multidimensional focus on its identification, epidemiology, pathogenesis, and therapeutic options.Archives of microbiology · 2026Review
- First report of Candidozyma auris in Vietnam.BMC microbiology · 2026Article
- Candida auris Testing by the Antimicrobial Resistance Laboratory Network, United States, 2022-2023.Emerging infectious diseases · 2026Article
- Candidemia in a tertiary hospital in Southern Brazil.Revista do Instituto de Medicina Tropical de Sao Paulo · 2026Article
- Mechanism of azole resistance inJournal of medical microbiology · 2025Article
- Direct Identification of Yeasts from Blood Cultures and Body Fluids Using MALDI-TOF MS with Concurrent Antifungal Susceptibility Testing.Mycopathologia · 2025Article
- Progression from Candida auris Colonization Screening to Clinical Case Status, United States, 2016-2023.Emerging infectious diseases · 2025Article
161 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeA systematic epidemiological study on intensive care unit (ICU)-acquired candidemia across India.
methodA prospective, nationwide, multicentric, observational study was conducted at 27 Indian ICUs. Consecutive patients who acquired candidemia after ICU admission were enrolled during April 2011 through September 2012. Clinical and laboratory variables of these patients were recorded. The present study is an analysis of data specific for adult patients.
resultsAmong 1,400 ICU-acquired candidemia cases (overall incidence of 6.51 cases/1,000 ICU admission), 65.2 % were adult. Though the study confirmed the already known risk factors for candidemia, the acquisition occurred early after admission to ICU (median 8 days; interquartile range 4-15 days), even infecting patients with lower APACHE II score at admission (median 17.0; mean ± SD 17.2 ± 5.9; interquartile range 14-20). The important finding of the study was the vast spectrum of agents (31 Candida species) causing candidemia and a high rate of isolation of Candida tropicalis (41.6 %). Azole and multidrug resistance were seen in 11.8 and 1.9 % of isolates. Public sector hospitals reported a significantly higher presence of the relatively resistant C. auris (8.2 vs. 3.9 %; p = 0.008) and C. rugosa (5.6 vs. 1.5 %; p = 0.001). The 30-day crude and attributable mortality rates of candidemia patients were 44.7 and 19.6 %, respectively. Logistic regression analysis revealed significant independent predictors of mortality including admission to public sector hospital, APACHE II score at admission, underlying renal failure, central venous catheterization and steroid therapy.
conclusionThe study highlighted a high burden of candidemia in Indian ICUs, early onset after ICU admission, higher risk despite less severe physiology score at admission and a vast spectrum of agents causing the disease with predominance of C. tropicalis.
Indexed as
Identifiers
25510301What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.